Literature DB >> 20392348

Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients.

A C Hesseling1, G Walzl, D A Enarson, N M Carroll, K Duncan, P T Lukey, C Lombard, P R Donald, K A Lawrence, R P Gie, P D van Helden, N Beyers.   

Abstract

BACKGROUND: Few biomarkers are available to identify tuberculosis (TB) patients at risk of delayed sputum conversion and relapse.
OBJECTIVES: To investigate whether baseline pre-treatment time to detection (TTD) of culture predicted 2-month bacteriological conversion and TB relapse.
METHODS: A total of 263 non-HIV-infected smear-positive previously untreated pulmonary TB patients were prospectively followed from diagnosis until treatment outcome after 6 months' treatment and TB recurrence within 24 months.
RESULTS: The median TTD was 3 days (range 1-17). Of 211 (80.2%) patients with favourable treatment outcome, 22 (10.4%) had recurrence, while 12 (5.7%) had confirmed relapse. Culture conversion at 2 months was associated in univariate analysis with the presence and number of cavities, extensive parenchymal involvement, male sex, sputum smear grading and TTD. In multiple logistic regression, TTD or smear grading and extensive parenchymal involvement both predicted month 2 conversion. Relapse was predicted by TTD, sex, body mass index, smear grading and number of cavities in univariate analysis, and in multivariate regression by TTD and sputum smear grading.
CONCLUSIONS: Baseline TTD and smear grading predicted month 2 culture conversion, relapse and also recurrence. These markers may be useful to identify non-HIV-infected patients at risk of recurrence, and may be relevant in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20392348

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  58 in total

1.  Pretreatment time to detection of Mycobacterium tuberculosis in liquid culture is associated with relapse after therapy.

Authors:  Charles M Bark; Bonnie A Thiel; John L Johnson
Journal:  J Clin Microbiol       Date:  2011-11-23       Impact factor: 5.948

2.  Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Authors:  Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

3.  A controlled trial of sputum induction and routine collection methods for TB diagnosis in a South African community.

Authors:  H D Geldenhuys; A Whitelaw; M D Tameris; D Van As; K K A Luabeya; H Mahomed; G Hussey; W A Hanekom; M Hatherill
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-15       Impact factor: 3.267

4.  Sputum volume predicts sputum mycobacterial load during the first 2 weeks of antituberculosis treatment.

Authors:  Miriam N Karinja; Tonya M Esterhuizen; Sven O Friedrich; Andreas H Diacon
Journal:  J Clin Microbiol       Date:  2014-12-31       Impact factor: 5.948

5.  Short-term storage does not affect the quantitative yield of Mycobacterium tuberculosis in sputum in early-bactericidal-activity studies.

Authors:  Eva Kolwijck; Melissa Mitchell; Amour Venter; Sven O Friedrich; Rod Dawson; Andreas H Diacon
Journal:  J Clin Microbiol       Date:  2013-01-23       Impact factor: 5.948

6.  Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial.

Authors:  Sven O Friedrich; Amour Venter; Xavier A Kayigire; Rodney Dawson; Peter R Donald; Andreas H Diacon
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

7.  Time to detection of Mycobacterium tuberculosis as an alternative to quantitative cultures.

Authors:  C M Bark; A Okwera; M L Joloba; B A Thiel; J G Nakibali; S M Debanne; W H Boom; K D Eisenach; J L Johnson
Journal:  Tuberculosis (Edinb)       Date:  2011-02-25       Impact factor: 3.131

8.  Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.

Authors:  Laura E Via; Dan Schimel; Danielle M Weiner; Veronique Dartois; Emmanuel Dayao; Ying Cai; Young-Soon Yoon; Matthew R Dreher; Robin J Kastenmayer; Charles M Laymon; J Eoin Carny; Joanne L Flynn; Peter Herscovitch; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

Review 9.  A systematic review of published literature describing factors associated with tuberculosis recurrence in people living with HIV in Africa.

Authors:  Yoshan Moodley; Kumeren Govender
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

10.  Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity.

Authors:  Xavier A Kayigire; Sven O Friedrich; Amour Venter; Rodney Dawson; Stephen H Gillespie; Martin J Boeree; Norbert Heinrich; Michael Hoelscher; Andreas H Diacon
Journal:  J Clin Microbiol       Date:  2013-04-17       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.